Use of hydroxychloroquine to prevent sars-cov-2 infection and treat mild covid-19: A systematic review and meta-analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorHospital Israelita Albert Einstein-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.creatorTanni, Suzana E.-
Autor(es): dc.creatorBacha, Hélio A.-
Autor(es): dc.creatorNaime, Alexandre-
Autor(es): dc.creatorBernardo, Wanderley M.-
Data de aceite: dc.date.accessioned2025-08-21T18:17:19Z-
Data de disponibilização: dc.date.available2025-08-21T18:17:19Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2020-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.36416/1806-3756/e20210236-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/229774-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/229774-
Descrição: dc.descriptionObjective: Chloroquine or hydroxychloroquine has demonstrated no effect on the treatment of hospitalized COVID-19 patients. This study aimed to answer questions related to the use of hydroxychloroquine for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection and in the treatment of patients with mild COVID-19 in terms of hospitalization, adverse events, and mortality. Methods: This was a systematic review and meta-analysis of phase 3 randomized clinical trials, selected from various databases, which compared patients who received hydroxychloroquine for SARS-CoV-2 prophylaxis or treatment of mild COVID-19 cases with controls. Results: A total number of 1,376 studies were retrieved. Of those, 9 met the eligibility criteria and were included in the study. No statistically significant differences were found between the hydroxychloroquine and control groups in terms of pre-or post-exposure prophylaxis of SARS-CoV-2 infection. The use of hydroxychloroquine increased the risk of adverse events by 12% (95% CI, 6-18%; p < 0.001), and the number needed to harm was 9. In addition, no significant differences were found between the hydroxychloroquine and control groups regarding hospitalization (risk difference [RD] = −0.02; 95% CI, −0.04 to 0.00; p = 0.14) or mortality (RD = 0.00; 95% CI, −0.01 to 0.02; p = 0.98) in the treatment of mild COVID-19. Conclusions: The use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection or treatment of patients with mild COVID-19 is not recommended.-
Descrição: dc.descriptionDisciplina de Pneumologia Departamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual Paulista-
Descrição: dc.descriptionHospital Israelita Albert Einstein-
Descrição: dc.descriptionDisciplina de Doenças Infecciosas Faculdade de Medicina de Botucatu Universidade Estadual Paulista-
Descrição: dc.descriptionFaculdade de Medicina Universidade de São Paulo-
Descrição: dc.descriptionDisciplina de Pneumologia Departamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual Paulista-
Descrição: dc.descriptionDisciplina de Doenças Infecciosas Faculdade de Medicina de Botucatu Universidade Estadual Paulista-
Idioma: dc.languageen-
Idioma: dc.languagept_BR-
Relação: dc.relationJornal Brasileiro de Pneumologia-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectHydroxychloroquine-
Palavras-chave: dc.subjectSARS-CoV-2-
Título: dc.titleUse of hydroxychloroquine to prevent sars-cov-2 infection and treat mild covid-19: A systematic review and meta-analysis-
Título: dc.titleUso de hidroxicloroquina para prevenir a infecção por sars-cov-2 e tratar covid-19 leve: uma revisão sistemática e meta-análise-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.